Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
2020 · Diabetologia · 82 citations
https://doi.org/10.1007/s00125-020-05277-3
Å
Åsa Ericsson
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
61
Papers
1.3K
Citations
19
h-index
27
i10-index
Åsa Ericsson is an academic researcher from Novo Nordisk (Denmark). The author has contributed to research in topics: Diabetes Treatment and Management & Diabetes Management and Research & Quantum Mechanics and Applications. The author has an h-index of 19, co-authored 52 publications.
ORCID: 0000-0002-3226-7469Papers by this author
worksSmart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis
2020 · Diabetes Therapy · 62 citations
https://doi.org/10.1007/s13300-020-00980-1
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
2017 · Applied Health Economics and Health Policy · 31 citations
https://doi.org/10.1007/s40258-016-0301-y
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective
2020 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.12845338
Evaluation of clinical benefits and economic value of weight loss in a <scp>Swedish</scp> population using a simulation model
2025 · Obesity · 0 citations
https://doi.org/10.1002/oby.24232
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat